More than 3 character to search
In amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), central and peripheral motoneurons are destroyed, accompanied by progressive loss of motor activity, muscle weakness, and atrophy. Usually, ALS lesions are generalized. Even in the absence of clinical manifestations, degenerative changes can be observed on electroneuromyography. Patients with ALS develop paralysis of the upper and lower extremities, speech, swallowing, breathing, and heart rhythm disorders.
Today, we can talk about slowing down the ALS progression, not cure. Methods of ALS treatment are still being studied quite actively. The well-known Ice Bucket Challenge, which was popular in 2014, aimed to obtain funds for ALS study.
The GOOD CELLS team is also studying this disease and doing everything possible to reduce its effects. As a treatment, we offer a combination of mesenchymal stem cells from adipose tissue (MSCs of adipose tissue) and neural crest-derived multipotent stem cells (NC-MSCs).
Therapeutic techniques include endolumbar, intravenous injection, and local administration of stem cells. It is important to repeat the injection every six months.
This treatment is indicated for patients over 18 y.o. with diagnosed amyotrophic lateral sclerosis.
Mesenchymal stem cells (MSCs) can differentiate into mesodermal cell lines and endoderm and ectoderm derivatives, including neurons and glial cells. For this reason, MSCs are widely studied as a therapeutic option for pathologies with poor results after pharmacological treatment. Such diseases include amyotrophic lateral sclerosis, which is characterized by the progressive death of motoneurons, causing motor disorders.
The full spectrum of MSCs action mechanisms has not been fully studied. Still, the results of numerous studies and our observations indicate the MSCs-mediate neurogenesis, stimulation of angiogenesis, anti-apoptotic, immunomodulatory, and anti-inflammatory effects. In addition, MSCs show the ability to go directly to the affected areas.
Thus, our proposed cell therapy can suspend the development of ALS. On average, precise results are noting 6 months after the introduction of MSCs.
The price of the program starts from $5,000, and it includes:
To learn more about the package, click the button below: